Piracetam
Piracetam, a nootropic. Prototype racetam (Giurgea 1964). Modulates AMPA glutamate receptors, increases membrane fluidity, improves cortical blood… Oral half-life 5 h.
Prototype racetam (Giurgea 1964). Modulates AMPA glutamate receptors, increases membrane fluidity, improves cortical blood flow. Weak cognitive effect in normal subjects; moderate effect in cognitive impairment / post-stroke.
ABSORPTION-RATE PROVENANCE: this value was derived by inverting the one-compartment peak-time relation in 2026-05-26-wave25-ka-from-tmax.ts, whose header claimed every peak time was verbatim from a primary human study. ALL FORTY-FOUR ENTRIES HAVE NOW BEEN CHECKED AND TWENTY-EIGHT FAIL. This one fails because the cited abstract mentions a delayed peak time under fed conditions and publishes no value — AND THIS IS ONE OF THE FOUR ENTRIES THE SCRIPT HEADER NAMED AS SPOT-CHECK RE-CONFIRMED. It is DISCLOSED RATHER THAN DELETED: a midpoint of a narrow range is usually inside the true spread, and removing it would fall back on the solver default of 1.0 per hour, which is worse for most of these records.
Pharmacokinetics
- Oral — t½ 5 h · F 100% · ka 8.33 h⁻¹ · Vd 42 L
Related compounds
- Alpha-GPC / choline — synergistic
Sources: PMID:16007238, PMID:41851591